The pre-print of a new study published in the Journal of Infection finds that antibody dependent enhancement (ADE) is a concern for COVID-19 vaccine recipients exposed to the SARS-COV-2 Delta variant. Bernadette Pajer with Informed Choice WA explains the results and addresses other COVID concerns.